Abstract
There is a strong impetus in the psychosis research field to develop interventions that aim to prevent the onset of psychotic disorders. Over the past 15 years there has been a tremendous development in the work aimed at understanding the pre-psychotic period. More recently there has been a focus on developing and testing treatments both pharmacological and psychological that could potentially prevent or delay the onset of psychosis. One of the psychological treatments that has received the most attention is cognitive behavioral therapy (CBT). Relatively few trials have been completed and this paper reviews the existing trials. Implications of these trials for the treatment of this early phase as well as for designing future studies are discussed.
Keywords: Cognitive behavioral therapy, prodromal psychosis, psychotic disorders, pre-psychotic period, ultra-high-risk criteria (UHR), Comprehensive Assessment of At Risk Mental State (CAARMS), antipsychotics, stress management, attenuated symptoms, psychological treatments
Current Pharmaceutical Design
Title: Cognitive Behavioral Therapy in Prodromal Psychosis
Volume: 18 Issue: 4
Author(s): Jean Addington, Catherine Marshall and Paul French
Affiliation:
Keywords: Cognitive behavioral therapy, prodromal psychosis, psychotic disorders, pre-psychotic period, ultra-high-risk criteria (UHR), Comprehensive Assessment of At Risk Mental State (CAARMS), antipsychotics, stress management, attenuated symptoms, psychological treatments
Abstract: There is a strong impetus in the psychosis research field to develop interventions that aim to prevent the onset of psychotic disorders. Over the past 15 years there has been a tremendous development in the work aimed at understanding the pre-psychotic period. More recently there has been a focus on developing and testing treatments both pharmacological and psychological that could potentially prevent or delay the onset of psychosis. One of the psychological treatments that has received the most attention is cognitive behavioral therapy (CBT). Relatively few trials have been completed and this paper reviews the existing trials. Implications of these trials for the treatment of this early phase as well as for designing future studies are discussed.
Export Options
About this article
Cite this article as:
Addington Jean, Marshall Catherine and French Paul, Cognitive Behavioral Therapy in Prodromal Psychosis, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316082
DOI https://dx.doi.org/10.2174/138161212799316082 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Specific Roles of NMDA Receptor Subunits in Mental Disorders
Current Molecular Medicine Hashimotos Thyroiditis: From Genes to the Disease
Current Genomics Mitochondrial Dysfunction and Its Relationship with mTOR Signaling and Oxidative Damage in Autism Spectrum Disorders
Mini-Reviews in Medicinal Chemistry Microvascular Thrombosis: An Exciting but Elusive Therapeutic Target in Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Nitric Oxide as a Marker for Levo-Thyroxine Therapy in Subclinical Hypothyroid Patients
Current Vascular Pharmacology FGF10 and FGF21 as Regulators in Adipocyte Development and Metabolism
Endocrine, Metabolic & Immune Disorders - Drug Targets Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Cytokines and their Antagonists as Therapeutic Agents
Current Medicinal Chemistry Genetic Engineering of Allergens for Immunotherapy
Inflammation & Allergy - Drug Targets (Discontinued) Early Biomarkers for Severe Drug Hypersensitivity Reactions
Current Pharmaceutical Design Targeting the Platelet Integrin GPIIb/IIIa
Current Pharmaceutical Design Rheumatoid Foot and Ankle Surgery
Current Rheumatology Reviews Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) Selective Glucocorticoid Receptor Ligands
Medicinal Chemistry Antihypertensive Therapy in Children: Differences in Medical Approach Between the United States and Europe
Current Medicinal Chemistry Preface [Hot Topic:Inflammatory Markers and Mediators: Emerging Therapeutic Targets in Diabetes, Cardiovascular and Metabolic Disorders (Guest Editor: Samuel Dagogo-Jack, MD)].
Current Drug Targets Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Zopiclone as Positive Control in Studies Examining the Residual Effects of Hypnotic Drugs on Driving Ability
Current Drug Safety Revisiting the ABCs of Multidrug Resistance in Cancer Chemotherapy
Current Pharmaceutical Biotechnology